Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report

Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report

BackgroundMetastatic colorectal cancer is one of the most common causes of cancer death worldwide. RAS and BRAF mutational analyses are strongly recommended before beginning chemotherapy in the metastatic setting for their predictive role for the efficacy of anti-EGFR monoclonal antibodies. In most...

Full description

Bibliographic Details
Main Authors:	Alfonso De Stefano, Nicoletta Zanaletti, Antonino Cassata, Lucrezia Silvestro, Anna Nappi, Rossana Casaretti, Carmela Romano, Francesca Foschini, Claudia Cardone, Marco Borrelli, Antonella Petrillo, Alfredo Budillon, Paolo Delrio, Antonio Avallone
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Oncology
Subjects:	case report anti-EGFR resistance intermittent strategy RAS BRAF
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1084681/full

Similar Items

Poorly differentiated thyroid cancer: Clinical, pathological, mutational, and outcome analysis
by: Amit Agarwal, et al.
Published: (2024-12-01)

Update on Fundamental Mechanisms of Thyroid Cancer
by: Alessandro Prete, et al.
Published: (2020-03-01)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
by: Baptiste Le Calvez, et al.
Published: (2020-07-01)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
by: Xue-Wu Wei, MD, et al.
Published: (2022-07-01)

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
by: Lisa Salvatore, et al.
Published: (2023-02-01)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018
by: Mesti Tanja, et al.
Published: (2023-03-01)

Developing Models to Predict <i>BRAF</i>V600E and <i>RAS</i> Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
by: Agnes Stephanie Harahap, et al.
Published: (2023-10-01)

Colorectal liver metastases patients prognostic assessment: prospects and limits of radiomics and radiogenomics
by: Vincenza Granata, et al.
Published: (2023-03-01)

Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAF<sup>V600E</sup>
by: Samar A. El-Kalyoubi, et al.
Published: (2023-05-01)

Activated Ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells
by: Jun eGong, et al.
Published: (2014-06-01)

Development of animal models to study aggressive thyroid cancers
by: Shovan Dutta, et al.
Published: (2025-02-01)

A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study
by: Tao Jiang, et al.
Published: (2024-07-01)

Colorectal Cancer with the BRAF V600E Mutation: Two Case Reports and Literature Review
by: Nguyen Cuong Pham, et al.
Published: (2024-09-01)

Somatic Mutations in Surgically Treated Colorectal Liver Metastases: An Overview
by: Jane Wang, et al.
Published: (2024-04-01)

NRAS-driven melanoma: A RAF can hide another
by: Sabine Druillennec, et al.
Published: (2017-11-01)

The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer
by: Omshree Shetty, et al.
Published: (2022-07-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports
by: Loc Carlo Bao, et al.
Published: (2024-03-01)

Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAF<sup>V600E</sup>
by: Alaa A. Hassan, et al.
Published: (2023-12-01)

Progress of research on molecular targeted therapies for colorectal cancer
by: Shilin Huang, et al.
Published: (2023-08-01)

The effect of sequential intermittent pneumatic compression of foot and calf on popliteal artery mean systolic blood flow in patients with intermittent claudication
by: Daphne Anthonysamy, et al.
Published: (2012-10-01)

A Bioinformatic Analysis Predicts That Cannabidiol Could Function as a Potential Inhibitor of the MAPK Pathway in Colorectal Cancer
by: Julianne du Plessis, et al.
Published: (2024-08-01)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
by: Twigger Katie, et al.
Published: (2012-08-01)

Detection of genetic mutations in 855 cases of papillary thyroid carcinoma by next generation sequencing and its clinicopathological features
by: Dongliang Shi, et al.
Published: (2024-11-01)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
by: Erik J. vanHelden, et al.
Published: (2019-11-01)

Exploring the molecular profile of localized colon cancer: insights from the AIO Colopredict Plus registry
by: Ira Ekmekciu, et al.
Published: (2024-11-01)

The Role and Importance of Molecular Tests in Approach to Thyroid Nodules
by: Levent Gürbüzler
Published: (2016-06-01)

Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population
by: Min Li, et al.
Published: (2020-05-01)

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies
by: Kozo Kataoka, et al.
Published: (2024-04-01)

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
by: Edoardo Isnaldi, et al.
Published: (2019-04-01)

Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update
by: Rajashri R. Naik, et al.
Published: (2023-01-01)

Effects of Intermittent Fasting on Weight Loss and Metabolic Health
by: Anna Kaźmierczak, et al.
Published: (2024-09-01)

Editorial: Recent advances in liquid biopsy in colorectal cancer
by: Claudia Cardone, et al.
Published: (2022-12-01)

Design and Application of Intermittent Gear Mechanism with Intermittent Ratio Continuous Adjustment
by: Li Zhijie, et al.
Published: (2017-01-01)

Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
by: Fumitaka Taniguchi, et al.
Published: (2021-12-01)

Prevalence of Papillary Thyroid Carcinoma is Significantly Higher in Graves Disease with Synchronous Thyroid Nodules
by: Mehmet KEFELI, et al.
Published: (2024-09-01)

Association of DNA Promoter Methylation and <i>BRAF</i> Mutation in Thyroid Cancer
by: Farzana Jasmine, et al.
Published: (2023-03-01)